1. Home
  2. LUNG vs PAL Comparison

LUNG vs PAL Comparison

Compare LUNG & PAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LUNG
  • PAL
  • Stock Information
  • Founded
  • LUNG 1995
  • PAL 2023
  • Country
  • LUNG United States
  • PAL United States
  • Employees
  • LUNG N/A
  • PAL N/A
  • Industry
  • LUNG Industrial Specialties
  • PAL
  • Sector
  • LUNG Health Care
  • PAL
  • Exchange
  • LUNG Nasdaq
  • PAL NYSE
  • Market Cap
  • LUNG 299.3M
  • PAL N/A
  • IPO Year
  • LUNG 2020
  • PAL 2024
  • Fundamental
  • Price
  • LUNG $7.37
  • PAL $9.92
  • Analyst Decision
  • LUNG Strong Buy
  • PAL Strong Buy
  • Analyst Count
  • LUNG 7
  • PAL 4
  • Target Price
  • LUNG $12.64
  • PAL $16.00
  • AVG Volume (30 Days)
  • LUNG 284.5K
  • PAL 289.7K
  • Earning Date
  • LUNG 04-30-2025
  • PAL 05-14-2025
  • Dividend Yield
  • LUNG N/A
  • PAL N/A
  • EPS Growth
  • LUNG N/A
  • PAL N/A
  • EPS
  • LUNG N/A
  • PAL N/A
  • Revenue
  • LUNG $83,789,000.00
  • PAL $147,414,098.00
  • Revenue This Year
  • LUNG $17.96
  • PAL $8.47
  • Revenue Next Year
  • LUNG $18.35
  • PAL $12.92
  • P/E Ratio
  • LUNG N/A
  • PAL N/A
  • Revenue Growth
  • LUNG 22.01
  • PAL N/A
  • 52 Week Low
  • LUNG $5.46
  • PAL $7.24
  • 52 Week High
  • LUNG $10.01
  • PAL $21.01
  • Technical
  • Relative Strength Index (RSI)
  • LUNG 46.93
  • PAL N/A
  • Support Level
  • LUNG $7.65
  • PAL N/A
  • Resistance Level
  • LUNG $8.12
  • PAL N/A
  • Average True Range (ATR)
  • LUNG 0.47
  • PAL 0.00
  • MACD
  • LUNG -0.07
  • PAL 0.00
  • Stochastic Oscillator
  • LUNG 23.03
  • PAL 0.00

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: